There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bioxcel Therapeutics (BTAI – Research Report) and KalVista Pharmaceuticals (KALV – Research Report) with bullish sentiments.
Bioxcel Therapeutics (BTAI)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics, with a price target of $11.00. The company’s shares closed last Thursday at $3.42.
According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bioxcel Therapeutics with a $12.71 average price target.
See Insiders’ Hot Stocks on TipRanks >>
KalVista Pharmaceuticals (KALV)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on KalVista Pharmaceuticals today and set a price target of $16.00. The company’s shares closed last Thursday at $10.84.
According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
KalVista Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $20.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BTAI:
- Biotech Alert: Searches spiking for these stocks today
- BioXcel Therapeutics price target lowered to $11 from $60 at H.C. Wainwright
- Largest borrow rate increases among liquid names
- Redfin upgraded, CSSE downgraded: Wall Street’s top analyst calls
- BioXcel Therapeutics price target lowered to $20 from $75 at Canaccord
